1. GPCR/G Protein
  2. Leukotriene Receptor

Leukotriene Receptor

Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.

Leukotriene Receptor Related Products (17):

Cat. No. Product Name Effect Purity
  • HY-13315
    Montelukast sodium Antagonist 99.82%
    Montelukast sodium is a potent, selective CysLT1 receptor antagonist.
  • HY-19989A
    MK-571 sodium salt Antagonist 99.24%
    MK571 sodium salt is a specific CysLT1 (Cysteinyl-Leukotriene Type 1 Receptor) antagonist.
  • HY-17492
    Zafirlukast Antagonist 98.70%
    Zafirlukast is a leukotriene receptor antagonist (LTRA).
  • HY-B0290A
    Pranlukast hemihydrate Antagonist 99.89%
    Pranlukast is an orally administered, selective, cysteinyl leukotriene receptor-1 antagonist, pranlukast, a widely used leukotriene C4, D4, and E4 antagonist, together with antibiotics could inhibit the progression to SOM.
  • HY-B0290
    Pranlukast Antagonist >98.0%
    Pranlukast is a selective cysteinyl leukotriene receptor antagonist.
  • HY-101946
    AS-35 Antagonist
    AS-35 is an orally effective, potent and selective antagonist of leukotrienes, with antiallergic activities.
  • HY-U00263
    LY210073 Antagonist
    LY210073 is a Leukotriene B4 (LTB4) receptor antagonist with an IC50 of 6.2 nM.
  • HY-U00253
    KP496 Antagonist
    KP496 is a selective, dual antagonist for Leukotriene D4 receptor and Thromboxane A2 receptor.
  • HY-13448
    Nedocromil Inhibitor
    Nedocromil is an inhaled anti-inflammatory agent for the preventive management of asthma.
  • HY-101438A
    Darbufelone mesylate Inhibitor
    Darbufelone mesylate is a dual inhibitor of cellular prostaglandin and leukotriene production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 μM) but is much less potent with PGHS-1 (IC50= 20 μM).
  • HY-U00027
    Quinotolast sodium Inhibitor
    Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits histamine and LTC4 release in a concentration-dependent manner.
  • HY-101676
    RG-12525 Antagonist
    RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4; Also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 µM.
  • HY-101686
    LM-1484 Antagonist
    LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for 3H-LTC4 sites.
  • HY-14938
    KCA 757 Antagonist
    KCA 757 is a sulfidopeptide leukotriene receptor antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.
  • HY-U00072
    RS-601 Antagonist
    RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.
  • HY-U00170
    U66858 Inhibitor
    U66858 is a potent inhibitor of LTB4 production in human whole blood. U66858 also exhibits significant inhibition of lipoxygenase and thromboxane A2 release.
  • HY-U00252
    ONO4057 Antagonist
    ONO4057 is a Leukotriene B4 receptor antagonist, with an IC50 of 0.7±0.3 μM.